Carcinoid heart disease

被引:26
作者
Connolly H.M. [1 ]
Pellikka P.A. [1 ]
机构
[1] Mayo Clinic, Rochester, MN 55905
关键词
Right Ventricular; Tricuspid Valve; Pulmonary Valve; Carcinoid Syndrome; Tricuspid Valve Replacement;
D O I
10.1007/s11886-006-0019-9
中图分类号
学科分类号
摘要
Progress in the medical and surgical management of patients with carcinoid disease has resulted in improved symptoms and survival. Carcinoid heart disease remains a major cause of morbidity and mortality among patients with malignant carcinoid syndrome. Limited medical treatment options are available for patients with symptomatic carcinoid heart disease. At the Mayo Clinic (Rochester, MN), we have taken an aggressive approach to severe valvular dysfunction from carcinoid heart disease. Patients with severe carcinoid heart disease currently are referred for cardiac operation when they develop cardiac symptoms, ventricular dysfunction, or (rarely) in anticipation of hepatic surgery. Surgical outcome depends on patient age and functional class at the time of cardiac surgery. Despite metastatic disease that limits longevity, cardiac surgical survivors usually demonstrate dramatic improvement in functional capacity. Cardiac surgery should be considered early for patients with symptomatic carcinoid heart disease and controlled carcinoid symptoms. An experienced medical, surgical, and anesthetic team approach to the patient with carcinoid heart disease is critical in order to provide state of the art management. Copyright © 2006 by Current Science Inc.
引用
收藏
页码:96 / 101
页数:5
相关论文
共 41 条
[1]  
Modlin I., Sandor A., An analysis of 8305 cases of carcinoid tumors, Cancer, 79, pp. 813-829, (1997)
[2]  
Moertel C., Karnofsky memorial lecture. An odyssey in the land of small tumors, J Clin Oncol, 5, pp. 1502-1522, (1987)
[3]  
Tomassetti P., Migliori M., Simoni P., Et al., Diagnostic value of plasma chromogranin A in neuroendocrine tumours, Eur J Gastroenterol Hepatol, 13, pp. 55-58, (2001)
[4]  
Stridsberg M., Oberg K., Li Q., Et al., Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours, J Endocrinol, 144, pp. 49-59, (1995)
[5]  
Kvols L., Moertel C., O'Connell M., Et al., Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue, N Engl J Med, 315, pp. 663-666, (1986)
[6]  
Kvols L., Buck M., Moertel C., Et al., Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995), Ann Intern Med, 107, pp. 162-168, (1987)
[7]  
Rubin J., Ajani J., Schirmer W., Et al., Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome, J Clin Oncol, 17, pp. 600-606, (1999)
[8]  
Que F., Nagorney D., Batts K., Et al., Hepatic resection for metastatic neuroendocrine carcinomas, Am J Surg, 169, pp. 36-42, (1995)
[9]  
Denney W., Kemp Jr. W., Anthony L., Et al., Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease, J Am Coll Cardiol, 32, pp. 1017-1022, (1998)
[10]  
Moller J., Connolly H., Rubin J., Et al., Factors associated with progression of carcinoid heart disease, N Engl J Med, 348, pp. 1005-1015, (2003)